A sensitive issue at the top
Your CEO has just been diagnosed with a potentially terminal disease: she may have six months or six years. She's come to discuss what you should say to the financial community. Should you disclose immediately? Should you wait to see how she responds to treatment?
A CEO's illness can be material news that will have an impact on the stock price; especially if the CEO has turned that company around or been key to its success. Take, for example, Disney's Eisner, Microsoft's Gates, or Berkshire
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495
Morgan Molthrop
Morgan Molthrop is vice president of investor relations at Infonet Services Corp in California
